Can “Botox in a bottle” really rival injectable neuromodulators? We examine the evidence behind topical peptide serums and Argireline.
|Articles|April 1, 2002
Dealing with epidermis
Dealing with epidermis
Advertisement
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Pritelivir for Refractory Mucocutaneous HSV in Immunocompromised Adults
2
EADV 2026 Atopic Dermatitis Highlights: Tilrekimig, RAC2 Inhibition, and Level Up Data
3
Topical vs Oral JAK Inhibitors for Vitiligo: How to Choose as Systemic Options Advance
4
Q&A: Falk G. Bechara, MD, on Long-Term Tunnel Control and Structural Damage in HS
5